• Aucun résultat trouvé

Medicinal Products Containing or Using in the Manufacturing Process of Animal and/or Human Origin

N/A
N/A
Protected

Academic year: 2022

Partager "Medicinal Products Containing or Using in the Manufacturing Process of Animal and/or Human Origin"

Copied!
1
0
0

Texte intégral

(1)

TERIPARATIDE 20µg/80µL solution for injection in pre-filled pen

Module 2 Section 2.3.R Page 1/1

- CONFIDENTIAL -

TER-MST-23r-v00-DCP

2.3.R. REGIONAL INFORMATION

Medicinal Products Containing or Using in the Manufacturing Process of Animal and/or Human Origin

No materials of animal and / or human origin are used in the manufacturing process of the drug product. The Declarations of Compliance with the Annex to Directive 75/318/EEC, as amended by Directive 1999/82/EEC relating to TSE are included in Section 3.2.R.

Medical Devices

Teriparatide pen-injector is a drug – device combination product, where the medicinal product provides the primary mode of action, within the meaning of the Directive 2001/83/EC and applicable amendments. The pen-injector represents the device constituent part of the combination product. The cartridge is integrated and non-replaceable.

The complete description of the pen device, covering materials of construction, principles of operation, manufacturer, design considerations, essential performance parameters and results of functional performance testing) can be found in Section 3.2.R-Annex 1.

In Section-3.2.R-Annex 2, the following information about Teriparatide pen-injector can be found:

- General description and suitability according to Guidance for CCS for Packaging Human Drugs and Biologics.

- Pen-injector performance according to requirements of Guidance for Industry and FDA Staff: Technical Considerations for Pen, Jet and Related Injectors Intended for Use with Drugs and Biological Products.

- Risk Management according to EN ISO 14971: Application of risk management to medical devices.

- Design controls according to ISO 13485 Medical devices quality management systems requirements for regulatory purposes.

- Design development summary (History of changes over the course of teriparatide pen- injector development program).

- Summary of the Design Verification studies conducted, which demonstrate that the pen- injector successfully met all criteria assessed and demonstrated compliance with ISO 11608-1:2014 and ISO 11608-2:2012, Section 11.4.3 Needle hub torque removal.

Références

Documents relatifs

2 TERMOSTATO ESTERNO THERMOSTAT THERMOSTAT RAUMTEMPERATURREGLER TERMOSTATO 3 SONDA AMBIENTE ROOM PROBE SONDE AMBIANT RAUMSONDE SONDA AMBIENTE 4 SONDA PELLET PELLET PROBE SONDE

B) Raccordement à l’aide du kit tuyau télescopique (option). Cette solution est celle à adopter en cas d’installation du foyer sur une cheminée

The present application of Travoprost/ Pharmathen 40 micrograms/mL preservative free eye drops, solution in multi dose container complies with the definition of a “hybrid”

Clinically significant hypotension or bradycardia should be treated as described in section 4.4. In relatively healthy non-ICU subjects treated with dexmedetomidine, bradycardia

breast and colorectal cancer, and if benefit- risk is considered favourable for the experimental regimen based on DFS and available safety and survival data, including PFS

Extrapolation of efficacy against an infectious disease from adults to paediatric patients is possible based on similar pathophysiology of the infectious disease and a spectrum

As explained in more detail in the Guideline on the role of the pharmacokinetics in the development of medicinal products in the paediatric population

Resolution EM/RC49/R.9 on Traditional Medicine adopted by the 49th Session of the Regional Committee for the Eastern Mediterranean Regional Workshop on Regulation of Herbal